Company
Headquarters: Marlborough, MA, United States
Employees: 319
CEO: Mr. Brian McKelligon
$105.1 Million
USD as of Jan. 1, 2025
Company | Market Cap (USD) |
---|---|
Intuitive | $216.79 B |
EssilorLuxottica SA | $116.96 B |
Becton, Dickinson and Company | $69.74 B |
HOYA Corp | $45.26 B |
Alcon Inc. | $41.55 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. It offers single-cell resolution with spatial context that provides a wealth of information to visualize tissue organization and disease pathology on a molecular level to understand disease progression and treatment response. The company also provides PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen, or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. In addition, it offers Proxima, a cloud-based platform designed to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Last Financial Reports Date | Dec. 31, 2023 |
Revenue TTM | $96.6 M |
EBITDA | $-47,142,000 |
Gross Profit TTM | $56.3 M |
Profit Margin | -65.53% |
Operating Margin | -33.31% |
Quarterly Revenue Growth | 24.80% |
Akoya Biosciences, Inc. has the following listings and related stock indices.
Stock: NASDAQ: AKYA wb_incandescent